Cell Production

Cell Production Center

Nearly 8000 square meters of production centers have been established in Chengdu, Kunming, and Beijing, relying on a forward-looking strategic layout to build a coverage of non base areas Due to the full chain, large-scale, and compliant GMP of modified immune cells, genetically modified immune cells, plasmids, and viral vectors Production system, committed to providing industry partners with internationally leading hardware facilities and process platforms, from research and development to business Integrated full lifecycle production services.

01 Non genetically modified immune cell line Realize full process pollution risk control

B+A-level biosafety cabinet production line

Production capacityConstruct four GMP production lines in Chengdu, Kunming, and Beijing, with an annual production capacity of over 1200 batches.
Process StandardStrictly following the current GMP standards for design and construction, with a B-class clean room as the background, the core operation is completed in an A-class air supply biosafety cabinet. Through strict separation of people and logistics, closed/semi closed operations, and environmental monitoring, the entire process of pollution risk control is achieved.
Quality systemEquipped with a complete verification monitoring system and strict aseptic control process, ensuring product safety, effectiveness, controllable quality, and achieving full traceability of production information.
C+A-level Closed Isolator Production Line

Production capacityThere are 5 C+A-level production lines built in Chengdu and Kunming, with an annual production capacity of up to 1500 batches.
Process StandardAgainst the backdrop of a C-level clean area, the core operations are carried out within an A-class sterile sealed isolator. The production line is equipped with independent channels for pedestrian and logistics, and materials are stored after passing the factory inspection. Through scientific layout, pollution is effectively controlled and confusion is prevented.

02 Gene modified immune cell production line Strong commercial supply capability

C+A-level sealed isolator

Capacity of productionThe annual production capacity can exceed 300 batches. Taking UCAR-T products as an example, a single batch can produce 100-200 servings, with a batch to batch difference (CV value) of less than 15%. The annual output can meet the treatment needs of over 30000 servings and has strong commercial supply capabilities.
Cost advantageThrough process innovation and large-scale production, the cost of single treatment can be significantly reduced by 20-30% compared to traditional autologous CAR-T. Meanwhile, the platform supports rapid switching between multiple targets, greatly enhancing the flexibility of research and production.

03 Plasmid production line Supply and service capabilities throughout the entire lifecycle

Ensure full controllability from the research and development source to the final product

Compliance FundamentalsStrictly follow the current GMP standards for design and construction, laying a solid foundation for product compliance declaration and listing.
Full process platformEstablish a proprietary process platform covering the entire process of plasmid construction, strain library construction, fermentation production, and quality control, ensuring full controllability from the research and development source to the final product.
Full-cycle serviceCapable of providing supply and service capabilities to support the entire lifecycle of drugs, from early development, clinical application (IND) to commercial application (BLA).

04 Virus production line 100% independently developed, optimized natural protease cleavage sequences through screening, and developed a new viral envelope structure

Combining the dual advantages of high viral titer and low cytotoxicity

Leading slow virus technology100% independently developed, through screening and optimizing natural protease cleavage sequences and developing a new viral envelope structure, efficient transduction can be achieved on difficult to transduce cells such as primary NK, gamma delta T, HSC, etc., with the dual advantages of high viral titer and low cytotoxicity.
Efficient and stable production systemAdopting a virus vector production system based on stable cell lines, no plasmid DNA is required, significantly reducing the cost of plasmids and transfection reagents. By simplifying the virus production process, the stability of the process is significantly improved. Paired with domestically produced automated enclosed production equipment, large-scale production can be achieved, effectively shortening the production cycle and significantly reducing production costs.

What do you want to inquire about?